GIANT BIOGENE (02367) Income Statement & Earnings

28.000
0.0000.00%

Trading May 20 15:33 CST

29.73BMarket Cap14.02P/E (TTM)

GIANT BIOGENE (02367) Income Statement

All

YOY

Hide blank lines

(FY)Dec 31, 2025

(Q6)Jun 30, 2025

(FY)Dec 31, 2024

(Q6)Jun 30, 2024

(FY)Dec 31, 2023

(Q6)Jun 30, 2023

(FY)Dec 31, 2022

(FY)Dec 31, 2021

(FY)Dec 31, 2020

(FY)Dec 31, 2019

Turnover

-0.37%5.52B

22.52%3.11B

57.17%5.54B

58.21%2.54B

49.05%3.52B

--1.61B

52.30%2.36B

30.41%1.55B

24.44%1.19B

--956.7M

Operating income

-0.37%5.52B

22.52%3.11B

57.17%5.54B

58.21%2.54B

49.05%3.52B

1.61B

52.30%2.36B

30.41%1.55B

24.44%1.19B

956.7M

Cost of sales

-9.40%-1.09B

-27.53%-570.32M

-71.90%-991.9M

-75.57%-447.19M

-56.28%-577.01M

---254.7M

-86.33%-369.21M

-8.04%-198.15M

-14.64%-183.41M

---159.99M

Operating expenses

-9.40%-1.09B

-27.53%-570.32M

-71.90%-991.9M

-75.57%-447.19M

-56.28%-577.01M

-254.7M

-86.33%-369.21M

-8.04%-198.15M

-14.64%-183.41M

-159.99M

Gross profit

-2.50%4.43B

21.46%2.54B

54.28%4.55B

54.94%2.09B

47.71%2.95B

1.35B

47.32%2B

34.48%1.35B

26.40%1.01B

796.71M

Selling expenses

-2.37%-2.06B

-18.67%-1.06B

-72.46%-2.01B

-60.67%-892.02M

-64.86%-1.16B

---555.18M

-104.03%-706.37M

-118.54%-346.21M

-68.91%-158.42M

---93.79M

Administrative expenses

-11.91%-168.48M

-25.87%-82.64M

-55.74%-150.54M

-38.26%-65.65M

12.98%-96.66M

---47.48M

-53.68%-111.07M

-119.07%-72.27M

-14.38%-32.99M

---28.85M

Research and development expenses

16.63%-88.79M

15.45%-41.18M

-42.06%-106.5M

-43.20%-48.7M

-70.22%-74.97M

---34.01M

-76.50%-44.04M

-86.49%-24.95M

-17.38%-13.38M

---11.4M

Impairment and provision

743.48%592K

124.29%119K

-113.14%-92K

-247.59%-490K

214.01%700K

--332K

-88.34%-614K

-113.15%-326K

342.09%2.48M

---1.02M

-Other impairment is provision

743.48%592K

124.29%119K

-113.14%-92K

-247.59%-490K

214.01%700K

--332K

-88.34%-614K

-113.15%-326K

342.09%2.48M

---1.02M

Special items of operating profit

30.25%229.82M

22.26%84.19M

32.18%176.45M

12.93%68.87M

199.11%133.49M

--60.98M

-28.41%44.63M

-63.00%62.35M

998.29%168.49M

--15.34M

Operating profit

-4.37%2.35B

25.02%1.44B

40.84%2.46B

48.94%1.16B

48.18%1.75B

775.64M

21.06%1.18B

-0.03%972.92M

43.76%973.24M

677M

Financing cost

-26.36%-302K

-129.63%-124K

-113.39%-239K

5.26%-54K

-433.33%-112K

---57K

---21K

----

Earning before tax

-4.37%2.35B

25.01%1.44B

40.84%2.46B

48.94%1.16B

48.17%1.75B

775.58M

21.05%1.18B

-0.03%972.92M

43.76%973.24M

677M

Tax

-10.00%-435.64M

-49.85%-261.7M

-33.39%-396.03M

-59.40%-174.64M

-68.53%-296.89M

---109.56M

-21.67%-176.16M

1.34%-144.79M

-44.14%-146.76M

---101.82M

After-tax profit from continuing operations

-7.13%1.91B

20.59%1.18B

42.36%2.06B

47.22%980.55M

44.59%1.45B

666.02M

20.95%1B

0.20%828.13M

43.69%826.49M

575.18M

Earning after tax

-7.13%1.91B

20.59%1.18B

42.36%2.06B

47.22%980.55M

44.59%1.45B

666.02M

20.95%1B

0.20%828.13M

43.69%826.49M

575.18M

Minority profit

71.94%-174K

113.81%361K

82.54%-620K

-185.06%-2.61M

-708.88%-3.55M

---917K

---439K

----

-99.85%35K

--22.92M

Profit attributable to shareholders

-7.15%1.91B

20.23%1.18B

42.06%2.06B

47.41%983.16M

44.88%1.45B

666.94M

21.00%1B

0.20%828.13M

49.65%826.45M

552.26M

Basic earnings per share

-12.86%1.83

15.15%1.14

40.94%2.1

47.76%0.99

50.51%1.49

0.67

19.28%0.99

0.00%0.83

50.91%0.83

0.55

Diluted earnings per share

-12.14%1.81

16.49%1.13

39.19%2.06

46.97%0.97

51.02%1.48

0.66

18.07%0.98

0.00%0.83

50.91%0.83

0.55

Currency Unit

CNY

Accounting Standards

IAS

Audit Opinions

Unqualified Opinion

Auditor

Ernst & Young

	(FY)Dec 31, 2025	(Q6)Jun 30, 2025	(FY)Dec 31, 2024	(Q6)Jun 30, 2024	(FY)Dec 31, 2023	(Q6)Jun 30, 2023	(FY)Dec 31, 2022	(FY)Dec 31, 2021	(FY)Dec 31, 2020	(FY)Dec 31, 2019
Turnover	-0.37%5.52B	22.52%3.11B	57.17%5.54B	58.21%2.54B	49.05%3.52B	--1.61B	52.30%2.36B	30.41%1.55B	24.44%1.19B	--956.7M
Operating income	-0.37%5.52B	22.52%3.11B	57.17%5.54B	58.21%2.54B	49.05%3.52B	1.61B	52.30%2.36B	30.41%1.55B	24.44%1.19B	956.7M
Cost of sales	-9.40%-1.09B	-27.53%-570.32M	-71.90%-991.9M	-75.57%-447.19M	-56.28%-577.01M	---254.7M	-86.33%-369.21M	-8.04%-198.15M	-14.64%-183.41M	---159.99M
Operating expenses	-9.40%-1.09B	-27.53%-570.32M	-71.90%-991.9M	-75.57%-447.19M	-56.28%-577.01M	-254.7M	-86.33%-369.21M	-8.04%-198.15M	-14.64%-183.41M	-159.99M
Gross profit	-2.50%4.43B	21.46%2.54B	54.28%4.55B	54.94%2.09B	47.71%2.95B	1.35B	47.32%2B	34.48%1.35B	26.40%1.01B	796.71M
Selling expenses	-2.37%-2.06B	-18.67%-1.06B	-72.46%-2.01B	-60.67%-892.02M	-64.86%-1.16B	---555.18M	-104.03%-706.37M	-118.54%-346.21M	-68.91%-158.42M	---93.79M
Administrative expenses	-11.91%-168.48M	-25.87%-82.64M	-55.74%-150.54M	-38.26%-65.65M	12.98%-96.66M	---47.48M	-53.68%-111.07M	-119.07%-72.27M	-14.38%-32.99M	---28.85M
Research and development expenses	16.63%-88.79M	15.45%-41.18M	-42.06%-106.5M	-43.20%-48.7M	-70.22%-74.97M	---34.01M	-76.50%-44.04M	-86.49%-24.95M	-17.38%-13.38M	---11.4M
Impairment and provision	743.48%592K	124.29%119K	-113.14%-92K	-247.59%-490K	214.01%700K	--332K	-88.34%-614K	-113.15%-326K	342.09%2.48M	---1.02M
-Other impairment is provision	743.48%592K	124.29%119K	-113.14%-92K	-247.59%-490K	214.01%700K	--332K	-88.34%-614K	-113.15%-326K	342.09%2.48M	---1.02M
Special items of operating profit	30.25%229.82M	22.26%84.19M	32.18%176.45M	12.93%68.87M	199.11%133.49M	--60.98M	-28.41%44.63M	-63.00%62.35M	998.29%168.49M	--15.34M
Operating profit	-4.37%2.35B	25.02%1.44B	40.84%2.46B	48.94%1.16B	48.18%1.75B	775.64M	21.06%1.18B	-0.03%972.92M	43.76%973.24M	677M
Financing cost	-26.36%-302K	-129.63%-124K	-113.39%-239K	5.26%-54K	-433.33%-112K	---57K	---21K	----	----	----
Earning before tax	-4.37%2.35B	25.01%1.44B	40.84%2.46B	48.94%1.16B	48.17%1.75B	775.58M	21.05%1.18B	-0.03%972.92M	43.76%973.24M	677M
Tax	-10.00%-435.64M	-49.85%-261.7M	-33.39%-396.03M	-59.40%-174.64M	-68.53%-296.89M	---109.56M	-21.67%-176.16M	1.34%-144.79M	-44.14%-146.76M	---101.82M
After-tax profit from continuing operations	-7.13%1.91B	20.59%1.18B	42.36%2.06B	47.22%980.55M	44.59%1.45B	666.02M	20.95%1B	0.20%828.13M	43.69%826.49M	575.18M
Earning after tax	-7.13%1.91B	20.59%1.18B	42.36%2.06B	47.22%980.55M	44.59%1.45B	666.02M	20.95%1B	0.20%828.13M	43.69%826.49M	575.18M
Minority profit	71.94%-174K	113.81%361K	82.54%-620K	-185.06%-2.61M	-708.88%-3.55M	---917K	---439K	----	-99.85%35K	--22.92M
Profit attributable to shareholders	-7.15%1.91B	20.23%1.18B	42.06%2.06B	47.41%983.16M	44.88%1.45B	666.94M	21.00%1B	0.20%828.13M	49.65%826.45M	552.26M
Basic earnings per share	-12.86%1.83	15.15%1.14	40.94%2.1	47.76%0.99	50.51%1.49	0.67	19.28%0.99	0.00%0.83	50.91%0.83	0.55
Diluted earnings per share	-12.14%1.81	16.49%1.13	39.19%2.06	46.97%0.97	51.02%1.48	0.66	18.07%0.98	0.00%0.83	50.91%0.83	0.55
Currency Unit	CNY	CNY	CNY	CNY	CNY	CNY	CNY	CNY	CNY	CNY
Accounting Standards	IAS	IAS	IAS	IAS	IAS	IAS	IAS	IAS	IAS	IAS
Audit Opinions	Unqualified Opinion	--	Unqualified Opinion	--	Unqualified Opinion	--	Unqualified Opinion	Unqualified Opinion	Unqualified Opinion	Unqualified Opinion
Auditor	Ernst & Young	--	Ernst & Young	--	Ernst & Young	--	Ernst & Young	Ernst & Young	Ernst & Young	Ernst & Young

FY: Financial Year. Refers to the 10-K file disclosed by the listed company to the SEC.

Q: Quarter. Refers to the 10-Q file disclosed by the listed company to the SEC. Q1, Q2, Q3, and Q4 are quarterly reports each with a span of 3 months; Q6 and Q9 are cumulative reports, with Q6 including 6 months and Q9 9 months.

China and the United States have successively adjusted multiple tariff and non-tariff measures, beginning to implement the consensus outcome Show More

牛牛課堂

Oct 13, 2025 18:05

[Opportunity Express] The US-China rivalry escalates! The rare earth industry becomes a "game-changer." How should investors respond?

Food流油

Apr 14, 2025 15:43

"Leaving the Group - Raising Taxes - Tweeting: The 'Money Making Strategy' of the Most Wild Gemini in Contemporary Times"